Conquering Overtreatment of DCIS: Lessons from PRECISION

• Published in: Cancer discovery Vol. 15; no. 1; pp. 28 - 33
• Main Authors: Bhattacharjee, Proteeti, Lips, Esther H., Sawyer, Elinor J., Hwang, E. Shelley, Thompson, Alastair M., Wesseling, Jelle, Behbod, Fariba, Collyar, Deborah, Davies, Helen, Futreal, Andrew, Jonkers, Jos, Navin, Nicholas, Nik-Zainal, Serena, Pinto, Donna, Rea, Daniel, Schmidt, Marjanka, Stobart, Hilary, Thompson, Alastair, van Oirsouw, Marja, van Rheenen, Jacco, Verschuur, Ellen, Wessels, Lodewyk F.A.
• Format: Journal Article
• Language: English
• Published: United States 13.01.2025
• Subjects: Breast Neoplasms - diagnosis; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Carcinoma, Intraductal, Noninfiltrating - diagnosis; Carcinoma, Intraductal, Noninfiltrating - pathology; Carcinoma, Intraductal, Noninfiltrating - therapy; Female; Humans; Medical Overuse - prevention & control; Overtreatment; Precision Medicine
• ISSN: 2159-8274; 2159-8290; 2159-8290
• DOI: 10.1158/2159-8290.CD-24-1201

As we cannot reliably distinguish indolent, low-risk ductal carcinoma in situ (DCIS) from potentially progressive, high-risk DCIS, all women with DCIS diagnosis undergo intensive treatment without any benefit. The PREvent ductal Carcinoma In Situ Invasive Overtreatment Now team was established to unravel DCIS biology and develop new multidisciplinary approaches for accurate risk stratification to tackle the global problem of DCIS overdiagnosis and overtreatment. See related article by Bressan et al., p. 16 See related article by Stratton et al., p. 22 See related article by Goodwin et al., p. 34